Recent Publications
Listed are publications with IIRC member as first and/or last author, regarding clinical studies led by IIRC members and/or other original studies published in SCOPUS/Google Scholar top-rated journals (based on lists in https://scholar.google.com/citations?view_op=top_venues&hl=en&vq=med and https://www.scopus.com/sources.uri).
Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates. Murray JD, Einhaus TK, Radtke S, Bar KJ, Peterson CW, Kiem HP. Blood Adv. 2025 Dec 1:bloodadvances.2025017838. doi: 10.1182/bloodadvances.2025017838. Online ahead of print. PMID: 41324589.
New Insights Into Factors Shaping CMV-Specific T-Cell Polyfunctionality After Hematopoietic Cell Transplantation. Sadowska-Klasa A, Lim FY, Xie H, Zamora D, Stevens-Ayers T, Leisenring WM, Edmison BC, De Rosa SC, Mielcarek M, Boeckh M. Am J Hematol. 2025 Dec 1. doi: 10.1002/ajh.70152. Online ahead of print. PMID: 41324241.
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis. Mehta RS, Sparapani RA, Kanakry CG, McCurdy SR, Saultz J, Lazaryan A, Milano F, Lee SJ. JAMA Oncol. 2025 Nov 6:e254551. doi: 10.1001/jamaoncol.2025.4551. Online ahead of print. PMID: 41196629.
Integrated transcriptomic landscape of medulloblastoma and ependymoma reveals novel tumor subtype-specific biology. Arora S, Nuechterlein N, Jensen M, Glatzer G, Sievers P, Varadharajan S, Korshunov A, Sahm F, Mack SC, Taylor MD, Gujral T, Holland EC. Neuro Oncol. 2025 Oct 24:noaf251. doi: 10.1093/neuonc/noaf251. Online ahead of print. PMID: 41159380.
Circulating neoantigen- and viral oncoprotein-specific CD8+ T cells share a transcriptional signature. Jani S, Bencomo T, Shasha C, Pulliam T, Jojic A, Church CD, Gooley TA, Koelle DM, Newell EW, Nghiem P. Cancer Immunol Res. 2025 Oct 23. doi: 10.1158/2326-6066.CIR-25-0082. Online ahead of print. PMID: 41129142.
IL-2/IL-15 signaling induces NK cell production of FLT3LG augmenting anti-PD-1 immunotherapy. Avanessian SC, van den Bijgaart RJE, Chew NW, Supper VM, Tang TT, Zhang Y, Zhao YQ, Abe K, Gauthier J, Barry KC. Cancer Immunol Res. 2025 Oct 13. doi: 10.1158/2326-6066.CIR-24-1259. Online ahead of print. PMID: 41081432.
Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation. Ueda Oshima M, Vo PT, Boeckh M, Bouvier ME, Carpenter PA, Mielcarek M, Petersdorf EW, Storb R, Gooley T, Sandmaier BM. J Clin Oncol. 2025 Oct 3:JCO2501238. doi: 10.1200/JCO-25-01238. Online ahead of print. PMID: 41043099.
Eomesodermin+ CD4+ T cells are critical for curative immunotherapy outcomes. Zhang P, Haeseleer F, Waltner OG, Gartlan KH, Bhise SS, Minnie SA, Adams RC, Yeh AC, Ensbey KS, Legg SRW, Sekiguchi T, Atilla E, Nemychenkov NS, Nelson EL, Joshi T, Liang EC, Hirayama AV, Abe K, Koyama M, Clouston AD, Gauthier J, Furlan SN, Hill GR. Immunity. 2025 Oct 2:S1074-7613(25)00415-7. doi: 10.1016/j.immuni.2025.09.004. Online ahead of print. PMID: 41043413.13.
Respiratory Virus Infections and Pulmonary Impairment after Allogeneic Hematopoietic Cell Transplantation. Cheng GS, Campbell AP, Xie H, Ogimi C, Waghmare A, Kuypers J, Nichols WG, Carpenter P, Corey L, Callais C, Sandmaier BM, Stevens-Ayers T, Jerome KR, Chien JW, Leisenring WM, Englund JA, Boeckh M. J Infect Dis. 2025 Oct 1:jiaf503. doi: 10.1093/infdis/jiaf503. Online ahead of print. PMID: 41027579.
Past Publications
RecOVARY? Using anti-Müllerian hormone to predict ovarian function after anti-HER2 therapy for early breast cancer. Symonds LK, Davidson NE. J Natl Cancer Inst. 2025 Sep 26:djaf247. doi: 10.1093/jnci/djaf247. Online ahead of print. PMID: 41005288. 5.
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation. Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO. J Clin Oncol. 2025 Sep 18:JCO2500206. doi: 10.1200/JCO-25-00206. Online ahead of print. PMID: 40966481.
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials. Ch'en PY, Zhang Y, Hippe DS, Akaike T, Miller NJ, Church C, Lachance K, Finberg A, Gooley T, Hall E, Bhatia S, Nghiem P. J Immunother Cancer. 2025 Sep 18;13(9):e012660. doi: 10.1136/jitc-2025-012660.PMID: 40973225.
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation. Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO. J Clin Oncol. 2025 Sep 18:JCO2500206. doi: 10.1200/JCO-25-00206. Online ahead of print. PMID: 40966481.
Damage-induced IL-18 stimulates thymic NK cells limiting endogenous tissue regeneration. Granadier D, Cooper K, Acenas D 2nd, Kousa A, Warren M, Hernandez V, Iovino L, deRoos P, Lederer EE, Shannon-Sevillano S, Kinsella S, Evandy C, van den Brink MRM, Lemarquis A, Dudakov JA. Nat Immunol. 2025 Sep 11. doi: 10.1038/s41590-025-02270-z. Online ahead of print. PMID: 40935830.
Polyomavirus Antibodies for Merkel Cell Carcinoma Recurrence Detection. Gunnell L, Hippe DS, Park SY, Fu A, Akaike T, Lachance K, Cahill K, Doolittle-Amieva C, Nghiem P. JAMA Dermatol. 2025 Sep 10:e253155. doi: 10.1001/jamadermatol.2025.3155. Online ahead of print. PMID: 40928768.
Approaches toward understanding human immunity. Brodin P, Wang F, Zhu B, Hammond T, Lu CP, Wimmers F, Zhernakova A, Liu W, Nadeau K, Prlic M. Immunity. 2025 Sep 9;58(9):2139-2143. doi: 10.1016/j.immuni.2025.08.011. PMID: 40930070.
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials. Portuguese AJ, Tuazon SA, Pont MJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu VQ, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Libby EN, Chapuis AG, Milano F, Riddell SR, Green DJ, Cowan AJ. Transplant Cell Ther. 2025 Sep 8:S2666-6367(25)01406-X. doi: 10.1016/j.jtct.2025.09.003. Online ahead of print. PMID: 40930223.
MicroRNAs as prognostic and predictive biomarkers among chronic myeloid leukemia patients in Addis Ababa, Ethiopia. Urgessa F, Jenkins I, Tsegaye A, Nigussie H, Kuru T, Gebremedhin A, Abdela F, Tadesse F, Radich J. Sci Rep. 2025 Aug 29;15(1):31844. doi: 10.1038/s41598-025-17371-w. PMID: 40883483. PMCID: PMC12397308.
Digital pathology and image analysis of p53 biomarker in lymphomas using two algorithms: correlation with genotype and visual inspection. Naik A, Kanzaria A, Chen X, Kaur N, Ho CJ, Smith SD, Gopal AK, Shadman M, Naresh KN. J Clin Pathol. 2025 Aug 25:jcp-2025-210280. doi: 10.1136/jcp-2025-210280. Online ahead of print. PMID: 40854792.
A Network for Advancing Prevention and Treatment of Infections Among Immunocompromised Individuals. Hill JA, Pergam SA, Halasa NB, Kumar D, Baden LR, Boeckh MJ. JAMA Netw Open. 2025 Aug 1;8(8):e2528383. doi: 10.1001/jamanetworkopen.2025.28383. PMID: 40844776.
A rescue fanconi anemia humanized mouse model with endogenous FA mutation and high human hematopoietic stem cell chimerism. Choo S, Tong AH, Fields E, Mack HM, Humbert O, Radtke S, Kiem HP. Mol Ther Methods Clin Dev. 2025 Jul 17;33(3):101528. doi: 10.1016/j.omtm.2025.101528. eCollection 2025 Sep 11. PMID: 40821852.
Pooled CAR-T screening in nonhuman primates identifies designs with enhanced proliferation, trafficking, and persistence. Maynard LH, Cavanaugh EJ, Zhu H, Starke CE, … Wilson E, Wessel C, Bushman F, Jerome KR, Kiem HP, Peterson CW. Blood. 2025 Aug 14:blood.2025028683. doi: 10.1182/blood.2025028683. Online ahead of print. PMID: 40811854.
Breast milk IgG engages the mouse neonatal immune system to instruct responses to gut antigens. Shenoy MK, Rico DM, Lorant AK, Touré H, Gordon S, Milburn LJ, Schwensen JS, Cabán ME, Koch MA. Science. 2025 Aug 14;389(6761):eado5294. doi: 10.1126/science.ado5294. Epub 2025 Aug 14. PMID: 40811558.
Fifth edition WHO classification: mature B-cell neoplasms. Naresh KN, Karube K, Borges A, Cheuk W, Gujral S, Sayed S, Sohani A, Lazzi S, Ott G, Du MQ, Leoncini L, Chan JKC. J Clin Pathol. 2025 Aug 12:jcp-2025-210260. doi: 10.1136/jcp-2025-210260. Online ahead of print. PMID: 40803815. Review.
Splenic EBV-positive inflammatory follicular dendritic cell sarcoma with fibroblastic/myoid immunophenotype in a patient with EBV-negative diffuse large B cell lymphoma. Love JE, Naresh KN. J Clin Pathol. 2025 Aug 12:jcp-2025-210303. doi: 10.1136/jcp-2025-210303. Online ahead of print. PMID: 40803814. Review.
Engraftment and persistence of HBB base-edited hematopoietic stem cells in nonhuman primates. Radtke S, Fields E, Swing K, Kanestrom G, Yen JS, Pande D, Enstrom MR, Humbert O, Weiss MJ, Liu DR, Newby GA, Kiem HP. Sci Transl Med. 2025 Aug 13;17(811):eadn2601. doi: 10.1126/scitranslmed.adn2601. Epub 2025 Aug 13. PMID: 40802741.
Methotrexate-induced epidermal necrosis. Kennedy C, Thompson JA. Clin Toxicol (Phila). 2025 Aug 12:1-2. doi: 10.1080/15563650.2025.2532616. Online ahead of print. PMID: 40792613. Case Report.
Innovation in active and passive immunisation of people who are immunocompromised: a call to action. Hill JA, Boonyaratanakornkit J, Mikulska M, Teh BW, Hahn WO, Haidar G, Liu C, Kumar D, Ison MG, Halasa N. Lancet Infect Dis. 2025 Aug 11:S1473-3099(25)00345-7. doi: 10.1016/S1473-3099(25)00345-7. Online ahead of print. PMID: 40812340. Review.
Regulation of CD45 isoforms during human effector and memory CD8 T cell differentiation: Implications for T cell nomenclature. McGuire DJ, Akondy RS, Yang S, Edupuganti S, Nagar S, Michael G, De Rosa SC, Newell EW, Farber DL, Kissick HT, McElrath MJ, Ahmed R. Proc Natl Acad Sci U S A. 2025 Aug 12;122(32):e2322982122. doi: 10.1073/pnas.2322982122. Epub 2025 Aug 5. PMID: 40763029.
Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade. Tachiki L, Moshiri Y, Hippe DS, Gong E, Zawacki L, Pulliam T, Lachance K, Church C, Fu A, Huynh E, Remington AJ, Harikrishnan N, Bierma M, Doolittle-Amieva C, Akaike T, Park SY, Alexander NA, Zaba L, Bhatia S, Nghiem PT. J Immunother Cancer. 2025 Aug 11;13(8):e012123. doi: 10.1136/jitc-2025-012123. PMID: 40789739.
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis. Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF .Am J Hematol. 2025 Aug 11. doi: 10.1002/ajh.70033. Online ahead of print. PMID: 40785644.
CD4+ T cell dysfunction in cancer. Venkatesh H, Fong L.J Exp Med. 2025 Sep 1;222(9):e20241417. doi: 10.1084/jem.20241417. Epub 2025 Aug 7. PMID: 40772965. Review.
A sitewise model of natural selection on individual antibodies via a transformer-encoder. Matsen FA 4th, Sung K, Johnson MM, Dumm W, Rich D, Starr T, Song YS, Bradley P, Fukuyama J, Haddox HK. Mol Biol Evol. 2025 Aug 5:msaf186. doi: 10.1093/molbev/msaf186. Online ahead of print. PMID: 40794593.
Early CD4+ T-cell proliferative burst and chronic T-cell engagement impact myeloma outcomes following T-cell engager therapy. Duffy AM, Goenka A, Azeem MI, Taz A, Potdar SV, Scott SA, Marin E, Kaufman JL, Hofmeister CC, Joseph NS, Gupta VA, Lonial S, Nooka AK, Dhodapkar MV, Dhodapkar KM. J Clin Invest. 2025 Jul 31:e192927. doi: 10.1172/JCI192927. Online ahead of print. PMID: 40762835.
Chimeric Antigen Receptor T-cell Therapy for Richter Transformation: A CIBMTR analysis. Nadiminti KV, Ahn KW, Patel J, Lian Q, … Hamadani M, Turtle CJ, Herrera AF, Shadman M. Transplant Cell Ther. 2025 Aug 1:S2666-6367(25)01334-X. doi: 10.1016/j.jtct.2025.07.021. Online ahead of print. PMID: 40754223.
Opportunities to improve antibiotic stewardship, and identification of blood biomarkers associated with bacteremia following CAR-T cell therapy. Ng SK, Flaherty PW, Ancheta M, Tindbaek KA, Sekhon MK, Huang JJ, Portuguese AJ, Albittar A, Kopmar NE, Cowan AJ, Shadman M, Hirayama AV, Till BG, Cassaday RD, Turtle CJ, Liu C, Xie H, Leisenring WM, Gauthier J, Liang EC, Hill JA. Transplant Cell Ther. 2025 Jul 31:S2666-6367(25)01335-1. doi: 10.1016/j.jtct.2025.07.022. Online ahead of print. PMID: 40752589.
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Parks KR, Moodie Z, Allen MA, Yen C, … Clark J, Riddler SA, Schief WR, McElrath MJ. Sci Transl Med. 2025 Jul 30;17(809):eady6831. doi: 10.1126/scitranslmed.ady6831. Epub 2025 Jul 30. PMID: 40737434. Clinical Trial.
CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia. Gang M, Othus M, Olix AC, Markey KA, Stirewalt DL, Connelly-Smith LS, Lee SJ, Milano F, Walter RB. Cancers (Basel). 2025 Jul 12;17(14):2323. doi: 10.3390/cancers17142323. PMID: 40723206. PMCID: PMC12293095.
Merkel Cell Carcinoma in Solid Organ Transplant Recipients: Prognosis and Response to Immunotherapy. Akaike T, Ch'en PY, Hippe DS, Gilmour MW, Gong E, Fu A, Singh N, Cahill K, Gunnell L, Vohra N, Hall E, Bhatia S, Lipson EJ, Blosser CD, Nghiem PT. Br J Dermatol. 2025 Jul 26:ljaf304. doi: 10.1093/bjd/ljaf304. Online ahead of print. PMID: 40713931.
Humoral determinants of checkpoint immunotherapy. Dai Y, Aizenbud L, Qin K, Austin M, Jaycox JR, Cunningham J, Wang EY, Zhang L, Fischer S, Carroll SM, van Aggelen H, Kluger Y, Herold KC, Furchtgott L, Kluger HM, Ring AM. Nature. 2025 Jul 23. doi: 10.1038/s41586-025-09188-4. Online ahead of print. PMID: 40702172.
Noncanonical and mortality-defining toxicities of CAR T cell therapy. Rejeski K, Hill JA, Dahiya S, Jain MD. Nat Med. 2025 Jul;31(7):2132-2146. doi: 10.1038/s41591-025-03813-5. Epub 2025 Jul 16.PMID: 40670774. Review.
First-line Therapy: Time-Limited Venetoclax Doublet Therapy. Huang J, Shadman M. Hematol Oncol Clin North Am. 2025 Jul 11:S0889-8588(25)00079-6. doi: 10.1016/j.hoc.2025.05.007. Online ahead of print. PMID: 40645851. Review.
Antiviral Monocytes Increase Prior to Detectable HIV-1 Rebound Viremia. Farrell-Sherman A, de la Force N, Prator CA, Valieris R, Azam W, Da Silva I, Deeks SG, Thanh C, Bosch RJ, Henrich TJ, Cohn LB. J Infect Dis. 2025 Jul 9:jiaf367. doi: 10.1093/infdis/jiaf367. Online ahead of print. PMID: 40628395.
Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in patients with High-Risk B-cell Lymphomas. Orozco JJ, Matesan MC, Lundberg SJ, Haaf RL, Miyaoka RS, Fisher DR, Gooley TA, Green DJ, Sandmaier BM, Martin PS, Gopal AK. Mol Cancer Ther. 2025 Jul 3. doi: 10.1158/1535-7163.MCT-24-0550. Online ahead of print. PMID: 40605797.
SF3B1K700E neoantigen is a CD8+ T-cell target shared across human myeloid neoplasms. Biernacki MA, Lok J, Foster KA, Cummings C, Busch S, Black RG, Ray S, Baquero Galvis L, Monahan T, Oh ST, Oehler VG, Stirewalt DL, Wu D, Deeg HJ, Doulatov S, Bleakley M. Cancer Immunol Res. 2025 Jun 26. doi: 10.1158/2326-6066.CIR-24-0091. Online ahead of print. PMID: 40569290.
Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hamad N, Burock K, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F. J Clin Oncol. 2025 Jun 25:JCO2402477. doi: 10.1200/JCO-24-02477. Online ahead of print. PMID: 40561385.
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm. Raychaudhuri S, Gooley TA, Rasmussen A, Quach K, Gill E, Halpern AB, Appelbaum JS, Ghiuzeli CM, Hendrie PC, Cassaday RD, Walter RB, Percival MM. Blood Neoplasia. 2025 Mar 3;2(3):100085. doi: 10.1016/j.bneo.2025.100085. eCollection 2025 Aug. PMID: 40535475. PMCID: PMC12171542.
The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy. Kampouri E, Flaherty P, Xie H, Sekhon MK, Chalal C, Stevens-Ayers TL, Green DJ, Gauthier J, Shadman M, Pérez-Osorio AC, Jerome KR, Leisenring WM, Boeckh MJ, Hill JA. Blood Adv. 2025 Jun 24;9(12):2997-3001. doi: 10.1182/bloodadvances.2024015164. PMID: 40203190.
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. Portuguese AJ, Liang EC, Huang JJ, Jeon Y, Dima D, Banerjee R, Kwok M, Cicero KI, Hirayama AV, Basom R, Khouderchah C, Shadman M, Fong L, Cowan AJ, Gauthier J. Haematologica. 2025 Jun 19. doi: 10.3324/haematol.2025.287985. Online ahead of print. PMID: 40534492.
Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Wuliji N, Jones SMW, Gooley T, Gerds AT, Medeiros BC, Shami PJ, Galvin J, Adekola K, Luger S, Baer MR, Rizzieri D, Wildes TM, Wang ES, Sekeres MA, Mukherjee S, Smith J, Garrison M, Kojouri K, Appelbaum J, Percival ME, Sandmaier BM, Lee S, Appelbaum FR, Rouce R, Sorror ML. Blood. 2025 Jun 19;145(25):3041-3051. doi: 10.1182/blood.2024027543. PMID: 40067123.
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin. Curtis DJ, Patil SS, Reynolds J, Purtill D, Lewis C, Ritchie DS, Gottlieb DJ, Yeung DT, Wong E, Tey SK, Perera T, Moore J, Koldej RM, De Abreu Lourenco R, Stubbs J, Morrissey CO, Munsef N, Arenas A, Hill GR; Australasian Leukaemia and Lymphoma Group. N Engl J Med. 2025 Jun 13. doi: 10.1056/NEJMoa2503189. Online ahead of print. PMID: 40513032.
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults without HIV. Huang Y, Zhang L, Lemos MP, Astronomo RD, Narpala S, Prabhakaran M, Garcia NMG, Lu Y, Mize GJ, Glantz H, Colegrove H, Mann P, Paez CA, Andersen-Nissen E, Hutter J, Dumond J, McDermott AB, Mascola JR, Koup RA, Bekker LG, McElrath MJ. J Clin Pharmacol. 2025 Jun 8. doi: 10.1002/jcph.70060. Online ahead of print. PMID: 40485091.
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence. Mazziotta F, Martin LE, Egan DN, Bar M, Kinsella S, Paulson KG, Voillet V, Lahman MC, Hunter D, Schmitt TM, Duerkopp N, Yeung CCS, Tang TH, Gottardo R, Asano Y, Wilcox EC, Lee B, Zhang T, Lopedote P, Penter L, Wu CJ, Milano F, Greenberg PD, Chapuis AG. Nat Commun. 2025 Jun 5;16(1):5214. doi: 10.1038/s41467-025-60394-0. PMID: 40473616. PMCID: PMC12141728
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study. Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, Calvo E, Medina L, Van Dongen M, Deville JL, Bernard-Tessier A, Ghosh D, Shotts K, Shen F, Jaiprasart P, Chaudhary R, Wu S, Cartee L, Schnepp R, Gaut D, Lauring J, Wang SC, Villalobos VM, Baldini C. J Clin Oncol. 2025 Jun 1:101200JCO2500678. doi: 10.1200/JCO-25-00678. Online ahead of print. PMID: 40450573.
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. Shadman M, Munir T, Ma S, Lasica M, Tani M, Robak T, Flinn IW, Brown JR, Ghia P, Ferrant E, Tam CS, Janowski W, Jurczak W, Xu L, Tian T, Lefebure M, Agresti S, Hirata J, Tedeschi A. J Clin Oncol. 2025 May 31:JCO2500758. doi: 10.1200/JCO-25-00758. Online ahead of print. PMID: 40448577. PMCID: PMC12141728.
BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation. Jacobs JM, Traeger L, Freese M, Barata A, Newcomb R, Rabideau D, Horick N, DeFilipp Z, Chen YB, Gray T, Pepper J, Caruso E, Amonoo HL, Lee SJ, Greer JA, Temel JS, El-Jawahri A .J Clin Oncol. 2025 May 30:JCO2500713. doi: 10.1200/JCO-25-00713. Online ahead of print. PMID: 40444925.
Disease Burden at the Time of Transplantation Is a Primary Predictor of Outcomes in Pediatric MDS: A Single-Center Experience. Dahlberg A, Stevenson P, Bhatt NS, Burroughs L, Carpenter PA, Summers C, Tarlock K, Thakar MS, Milano F, Deeg HJ, Bleakley M. Cancers (Basel). 2025 May 13;17(10):1645. doi: 10.3390/cancers17101645.PMID: 40427141. PMCID: PMC12109966
Choosing between HLA-Mismatched Unrelated and Haploidentical donors: Donor age considerations. Mehta RS, Schmidt G, Williams K, Patel SA, Schetelig J, Savani B, Askar M, Petersdorf E, Ringden O, Kanakry CG, Kanakry JA, Stefanski H, Arrieta-Bolaños E, Betts B, Benjamin C, Gadalla S, Wang T, Saultz J, Spellman S, Jurdi NE, Bolon YT, Lee SJ. Transplant Cell Ther. 2025 May 24:S2666-6367(25)01203-5. doi: 10.1016/j.jtct.2025.05.019. Online ahead of print. PMID: 40419020.
American Society for Transplantation and Cellular Therapy Series #9: Management of HHV-6B After Hematopoietic Cell Transplantation and Chimeric Antigen Receptor (CAR)-T-Cell Therapy. Kampouri E, Handley G, Phan TL, Lee YJ, Shaw R, Carpenter PA, Dadwal SS, Chemaly RF, Papanicolaou GA, Ogata M, Boeckh M, Zerr DM, Hill JA. Transplant Cell Ther. 2025 May 21:S2666-6367(25)01164-9. doi: 10.1016/j.jtct.2025.05.001. Online ahead of print. PMID: 40409689.
Targeting neutrophils for cancer therapy. Kwak JW, Houghton AM. Nat Rev Drug Discov. 2025 May 15. doi: 10.1038/s41573-025-01210-8. Online ahead of print. PMID: 40374764. Review.
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Willis JR, … McElrath MJ, Edupuganti S, Taylor BS, Diemert D, Ozorowski G, Koup RA, Montefiori D, Ward AB, Hedestam GK, Tomaras G, Hunt DJ, Muema D, Sok D, Laufer DS, Andrews SF, Nduati EW, Schief WR. Science. 2025 May 15:eadr8382. doi: 10.1126/science.adr8382. Online ahead of print. PMID: 40373112.
Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Ely ZA, Kulstad ZJ, Gunaydin G, Addepalli S, Verzani EK, Casarrubios M, Clauser KR, Wang X, Lippincott IE, Louvet C, Schmitt T, Kapner KS, Agus MP, Hennessey CJ, Cleary JM, Hadrup SR, Klaeger S, Su J, Jaeger AM, Wolpin BM, Raghavan S, Smith EL, Greenberg PD, Aguirre AJ, Abelin JG, Carr SA, Jacks T, Freed-Pastor WA. Science. 2025 May 8;388(6747):eadk3487. doi: 10.1126/science.adk3487. Epub 2025 May 8. PMID: 40339010.
Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results. Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, Rao SS, Farber CM, Cohen AC, Yao H, Idoine A, An Q, Flinn IW, Sharman JP. Blood Adv. 2025 May 7:bloodadvances.2024015493. doi: 10.1182/bloodadvances.2024015493. Online ahead of print. PMID: 40334067.
ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients. Zamora D, Xie H, Wong E, Santiano C, Vivas-Jimenez A, Sadowska-Klasa A, Kampouri E, Stevens-Ayers T, Ueda Oshima M, Leisenring WM, Hill JA, Boeckh M. Bone Marrow Transplant. 2025 May 6. doi: 10.1038/s41409-025-02611-4. Online ahead of print. PMID: 40328898.
Transient silencing of hypermutation preserves B cell affinity during clonal bursting. Pae J, Schwan N, Ottino-Loffler B, DeWitt WS, Garg A, Bortolatto J, Vora AA, Shen JJ, Hobbs A, Castro TBR, Mesin L, Matsen FA 4th, Meyer-Hermann M, Victora GD. Nature. 2025 Mar 19. doi: 10.1038/s41586-025-08687-8. Online ahead of print. PMID: 40108454
Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients. Gong E, Zawacki L, Fan X, Hippe DS, Menon AA, Remington AJ, Lachance K, Akaike T, Tachiki L, Park SY, Nghiem P. BMJ Oncol. 2025 Mar 6;4(1):e000654. doi: 10.1136/bmjonc-2024-000654. eCollection 2025. PMID: 40099002. PMCID: PMC11911694
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up. Portuguese AJ, Huang JJ, Jeon Y, Taheri M, Albittar A, Liang EC, Hirayama AV, Kimble EL, Iovino L, Poh C, Gopal AK, Shadman M, Till BG, Milano F, Chapuis AG, Otegbeye F, Cassaday RD, Basom RS, Wu QV, Maloney DG, Gauthier J. Haematologica. 2025 Mar 13. doi: 10.3324/haematol.2024.287010. Online ahead of print. PMID: 40079097
Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy. Paulson KG, Park SY, Bhatia S, Hippe DS, Nghiem P. J Am Acad Dermatol. 2025 Mar 10:S0190-9622(25)00422-0. doi: 10.1016/j.jaad.2025.03.006. Online ahead of print. PMID: 40074150
Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction. Filipp M, Ge ZD, DeBerge M, Lantz C, Glinton K, Gao P, Smolgovsky S, Dai J, Zhao YY, Yvan-Charvet L, Alcaide P, Weinberg SE, Schiattarella GG, Hill JA, Feinstein MJ, Shah SJ, Thorp EB. Circulation. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.070248. Online ahead of print. PMID: 40071347
T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy. Kinoshita H, Walti CS, Webber K, Pezzella G, Jensen-Wachspress M, Lang H, Shuey K, Boonyaratanakornkit J, Pergam SA, Chu HY, Bollard CM, Keller MD, Hill JA. Transplant Cell Ther. 2025 Mar 1:S2666-6367(25)01053-X. doi: 10.1016/j.jtct.2025.02.019. Online ahead of print. PMID: 40032074
In the activation of HPV-specific human B cells HPV-VLP vaccines mimic membrane-associated antigens. Torgbor C, Sohn H, Dizon BLP, Mutic EC, George R, Kwak K, Akkaya M, Ulker EB, Traver M, Brzostowski J, Galloway DA, Thompson CD, Çuburu N, Schiller JT, Pierce SK. Proc Natl Acad Sci U S A. 2025 Mar 11;122(10):e2414514122. doi: 10.1073/pnas.2414514122. Epub 2025 Mar 3. PMID: 40030014
The Association of HLA-E Ligand and NKG2 Receptor Variation With Relapse and Mortality After Haploidentical Related Donor Transplantation. Petersdorf EW, McKallor C, Malkki M, Hsu K, He M, Spellman SR, Gooley T, Stevenson P. Transplant Cell Ther. 2025 Mar;31(3):137-156. doi: 10.1016/j.jtct.2025.01.004. Epub 2025 Jan 9.PMID: 39798802
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. Lee SM, Hamid O, Jotte R, Zakharia Y, Medina T, Gillespie-Twardy A, Mehmi I, Chandra S, Watson G, Ward P, Chaney M, Lu H, Berndt J, O'Connor BP, Rathi K, Shaikh E, Cowey CL. Clin Cancer Res. 2025 Mar 3;31(5):848-859. doi: 10.1158/1078-0432.CCR-24-1478.PMID: 39786430
Sequential JAK inhibition enhances anti-tumor immunity after combined anti-PD-1 and anti-CTLA4. Arias-Badia M, Chen P, Lwin YM, Srinath A, Lyu A, Fan Z, Kwek SS, Luong DN, Setayesh A, Sakamoto M, Clark M, Lea A, Wolters RM, Goodearl A, Harding FA, Gorman JV, Ritacco W, Fong L. JCI Insight. 2025 Feb 27:e187921. doi: 10.1172/jci.insight.187921. Online ahead of print. PMID: 40014402
Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy. Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D.Cancer Manag Res. 2025 Feb 19;17:357-372. doi: 10.2147/CMAR.S510408. eCollection 2025. PMID: 39990276
Long-Term Outcomes and Quality of Life with Treosulfan-Based Conditioning in Hematological Malignancies. Mehta RS, Lee SJ, Gooley TA, Thur L, Dahlberg A, Delaney C, Gyurkocza B, Vo PT, Deeg HJ, Milano F. Blood Adv. 2025 Feb 19:bloodadvances.2024015392. doi: 10.1182/bloodadvances.2024015392. Online ahead of print. PMID: 39969207
Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Galsky MD, Autio KA, Cabanski CR, Wentzel K, Graff JN, Friedlander TW, Howes TR, Shotts KM, Densmore J, Spasic M, Da Silva DM, Chen RO, Lata J, Skolnik J, Keler T, Yellin MJ, LaVallee TM, Fairchild J, Boffo S, O'Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi SK, Fong L. Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-3693. Online ahead of print. PMID: 39964352
Modulators of relapse risk in adults allografted for acute myeloid leukemia in measurable residual disease-positive remission. Gang M, Othus M, Sandmaier BM, Davis C, Basom RS, Walter RB. Bone Marrow Transplant. 2025 Feb 17. doi: 10.1038/s41409-025-02533-1. PMID: 39962220
RNA polymerase II at histone genes predicts outcome in human cancer. Henikoff S, Zheng Y, Paranal RM, Xu Y, Greene JE, Henikoff JG, Russell ZR, Szulzewsky F, Thirimanne HN, Kugel S, Holland EC, Ahmad K. Science. 2025 Jan 2;387(6735):737-743. doi: 10.1126/science.ads2169. Epub 2025 Feb 13. PMID: 39946483
MorPhiC Consortium: towards functional characterization of all human genes. Adli M, Przybyla L, Burdett T, Burridge PW, Cacheiro P, Chang HY, Engreitz JM, Gilbert LA, Greenleaf WJ, Hsu L, Huangfu D, Hung LH, Kundaje A, Li S, Parkinson H, Qiu X, Robson P, Schürer SC, Shojaie A, Skarnes WC, Smedley D, Studer L, Sun W, Vidović D, Vierbuchen T, White BS, Yeung KY, Yue F, Zhou T; MorPhiC Consortium. Nature. 2025 Feb;638(8050):351-359. doi: 10.1038/s41586-024-08243-w. Epub 2025 Feb 12. PMID: 39939790. Review.
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martínez-Cibrian N, Shune L, Shadman M. Blood. 2025 Feb 12:blood.2024026831. doi: 10.1182/blood.2024026831. PMID: 39938007
Longitudinal Tear Cytokine Biomarkers: An Analysis from the Close Assessment and Testing for Chronic Graft-Versus-Host Disease (CATCH) Protocol. El Jurdi N, Hamilton BK, Pidala JA, Onstad L, Mun C, Jain S, Lee SJ. Transplant Cell Ther. 2025 Feb 7:S2666-6367(25)01009-7. doi: 10.1016/j.jtct.2025.02.004. PMID: 39923937
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT. Eur Urol Oncol. 2025 Feb 6:S2588-9311(25)00002-1. doi: 10.1016/j.euo.2025.01.002. PMID: 39920014
APMAT analysis reveals the association between CD8 T cell receptors, cognate antigen, and T cell phenotype and persistence. Xie J, Chen DG, Chour W, Ng RH, Zhang R, Yuan D, Choi J, McKasson M, Troisch P, Smith B, Jones L, Webster A, Rasheed Y, Li S, Edmark R, Hong S, Murray KM, Logue JK, Franko NM, Lausted CG, Piening B, Algren H, Wallick J, Magis AT, Watanabe K, Mease P, Greenberg PD, Chu H, Goldman JD, Su Y, Heath JR. Nat Commun. 2025 Feb 6;16(1):1402. doi: 10.1038/s41467-025-56659-3. PMID: 39915487.
Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine. Carter JJ, Smith RA, Scherer EM, Skibinski DAG, Sankaranarayanan S, Luxembourg A, Kollmann T, Marty KD, Sadarangani M, Dobson S, Galloway DA. Vaccine. 2025 Feb 5;50:126817. doi: 10.1016/j.vaccine.2025.126817. PMID: 39914257.
Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma. Takayesu JSK, Parvathaneni U, Laramore GE, Panjwani N, Sillings J, Futran ND, Humphreys IM, Jafari A, Abuzeid WM, Barber B, Marchiano E, Lee SM, Thompson JA, Hall E, Bhatia S, Rodriguez CP, Liao JJ. Cancer Rep (Hoboken). 2025 Feb;8(2):e70111. doi: 10.1002/cnr2.70111. PMID: 39907094.
Factors associated with early quality of life response to palliative care during hematopoietic cell transplantation. Newcomb RA, Amonoo HL, Kavanaugh AR, Wharton KC, Rowland M, Fausto J, Webb JA, Jackson V, Greer JA, Temel JS, Lark P, Rabideau DJ, O'Brien K, LeBlanc TW, Lee SJ, El-Jawahri A. Blood Adv. 2025 Feb 5:bloodadvances.2024014574. doi: 10.1182/bloodadvances.2024014574. PMID: 39908568.
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, Plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Ko AH, Chao J, Noel MS, Shankaran V, Sohal D, Crow M, Oberstein PE, Scott AJ, McRee AJ, Rocha Lima CMSP, Fong L, Keenan BP, Soto M, Filbert EL, Hsu FJ, Yang X. Cancer Res Commun. 2025 Feb 5. doi: 10.1158/2767-9764.CRC-24-0513. PMID: 39907035.
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study. Garrett N, Tapley A, Hudson A, … McElrath MJ, Kublin JG, Bekker LG, Gilbert PB, Corey L, Gray GE, Huang Y, Kotze P; CoVPN 3008 Ubuntu Study Team. EClinicalMedicine. 2025 Jan 20;80:103054. doi: 10.1016/j.eclinm.2024.103054. eCollection 2025 Feb. PMID: 39902315. PMCID: PMC11788791.
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies. Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, MacMillan HR, Wu QV, Muhunthan V, Berger C, Pullarkat S, Wright JH, Yeung CCS, Hyun TS, Seaton B, Aicher LD, Song X, Pierce RH, Lo Y, Cole GO, Lee SM, Newell EW, Maloney DG, Riddell SR. Clin Cancer Res. 2025 Feb 3;31(3):503-514. doi: 10.1158/1078-0432.CCR-24-2172.PMID: 39466024.
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. Bhatia S, Topalian SL, Sharfman W, Meyer T, Steven N, Lao CD, Fariñas-Madrid L, Devriese LA, Moore K, Ferris RL, Honma Y, Elias I, Srirangam A, Garnett-Benson C, Lee M, Nghiem P. J Clin Oncol. 2025 Jan 31:JCO2402138. doi: 10.1200/JCO-24-02138. PMID: 39889250.
Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damage. Lemarquis AL, Kousa AI, Argyropoulos KV, Jahn L, Gipson B, Pierce J, Serrano-Marin L, Victor K, Kanno Y, Girotra NN, Andrlova H, Tsai J, Velardi E, Sharma R, Grassmann S, Ekwall O, Goldstone AB, Dudakov JA, DeWolf S, van den Brink MRM. Immunity. 2025 Jan 28:S1074-7613(25)00031-7. doi: 10.1016/j.immuni.2025.01.006. PMID: 39892391 4.
Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML. Vo PT, Sandmaier BM, Othus M, Ali N, Rodríguez-Arbolí E, Orvain C, Davis C, Basom RS, Storb R, Walter RB. Bone Marrow Transplant. 2025 Jan 29. doi: 10.1038/s41409-025-02516-2. Online ahead of print. PMID: 39881206.
ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV. Pinto-Santini D, Jalil EM, Fernandes GT, Hilaire G, Kolevic L, Cabello R, Grinsztejn B, Pape W, Deschamps MM, House MG, Brofsky E, Sahasrabuddhe VV, Dasgupta S, Pasalar S, Madeleine MM, Carter J, Prabhu PR, Galloway D, Duerr A. BMC Cancer. 2025 Jan 27;25(1):151. doi: 10.1186/s12885-025-13551-z. PMID: 39871186. PMCID: PMC11771066.
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203. Othus M, Garcia-Manero G, Appelbaum FR, Erba HP, Dietrich E, Raychaudhuri S, Appelbaum J, Estey E, Percival ME. Leukemia. 2025 Jan 27. doi: 10.1038/s41375-024-02512-3. Online ahead of print. PMID: 39870766.
Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect. Reddi S, Senyshyn L, Ebadi M, Podlesny D, Minot SS, Gooley T, Kabage AJ, Hill GR, Lee SJ, Khoruts A, Rashidi A. Nat Commun. 2025 Jan 25;16(1):1034. doi: 10.1038/s41467-025-56375-y. PMID: 39863610. PMCID: PMC11762788.
ACQUIRED MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY CLL WHO PROGRESSED IN THE ALPINE STUDY. Brown JR, Li J, Eichhorst B, Lamanna N, O'Brien SM MD, Tam CS, Qiu L, Huang R, Shi Y, Idoine A, Salmi T, Cohen AC, Shadman M. Blood Adv. 2025 Jan 24:bloodadvances.2024014206. doi: 10.1182/bloodadvances.2024014206. Online ahead of print. PMID: 39853273.
Phase I study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult B-ALL patients. Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu QV, Jaeger-Ruckstuhl CA, Pender BS, Kirchmeier DR, Torkelson A, Braathen K, Basom R, Shadman M, Kopmar NE, Cassaday RD, Riddell SR, Maloney DG, Turtle CJ. Blood Adv. 2025 Jan 16:bloodadvances.2024015314. doi: 10.1182/bloodadvances.2024015314. Online ahead of print. PMID: 39820359.
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Vitanza NA, Ronsley R, Choe M, … Wendler JP, Park JR, Jensen MC. Nat Med. 2025 Jan 7. doi: 10.1038/s41591-024-03451-3. Online ahead of print. PMID: 39775044
Endogenous thymic regeneration: restoring T cell production following injury. Granadier D, Acenas D 2nd, Dudakov JA. Nat Rev Immunol. 2025 Jan 6. doi: 10.1038/s41577-024-01119-0. Online ahead of print. PMID: 39762553. Review.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Lopez J, Powles T, Braiteh F, … , Fong L, … , Sahin U, Türeci Ö, Camidge DR. Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03334-7. Online ahead of print. PMID: 39762422.
Pre-Transplant Chromosome Genomic Array Testing Improves Prognosis for Myelofibrosis Patients Undergoing Transplantation. Qu X, Stevens E, Fitzgibbon MP, Beppu L, Monahan TM, Yeung C, Stirewalt DL, Wu D, Radich JP, Deeg HJ, Fang M. Transplant Cell Ther. 2024 Dec 23:S2666-6367(24)00837-6. doi: 10.1016/j.jtct.2024.12.018. Online ahead of print. PMID: 39722322
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study. Ghosh N, Eyre TA, Brown JR, Lamanna N, Manzoor BS, Coombs CC, Tuncer HH, Ujjani C, Leslie LA, Roeker LE, Davids MS, Rhodes JM, Skarbnik AP, Sinai W, Fleury I, Hill BT, Martinez-Calle N, Barr PM, Jawaid D, Emechebe N, Pearson L, Lansigan F, Choi Y, Jensen CE, Fakhri B, Stephens DM, Marx SE, Schuster SJ, Coyle M, Pivneva I, Watson T, Guerin A, Shadman M. Am J Hematol. 2024 Dec 19. doi: 10.1002/ajh.27563. Online ahead of print. PMID: 39698781
Four-component protein nanocages designed by programmed symmetry breaking. Lee S, Kibler RD, Ahn G, Hsia Y, Borst AJ, Philomin A, Kennedy MA, Huang B, Stoddard B, Baker D. Nature. 2024 Dec 18. doi: 10.1038/s41586-024-07814-1. Online ahead of print. PMID: 39695226
Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia. Orvain C, Milano F, Rodríguez-Arbolí E, Othus M, Petersdorf EW, Sandmaier BM, Appelbaum FR, Walter RB. Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02497-z. Online ahead of print. PMID: 39668236
Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y, Pan X, Wang Z, Chen DG, Zhu H, Greenberg PD, Li G. Cancer Cell. 2024 Dec 3:S1535-6108(24)00438-0. doi: 10.1016/j.ccell.2024.11.003. Online ahead of print. PMID: 39642888
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, Starzinski A, Wolters R, Arias-Badia M, Allaire K, Wu K, Gurunathan V, Valderrábano L, Wei XX, Miller RA, Van Allen EM, Fong L. Nature. 2024 Dec 4. doi: 10.1038/s41586-024-08290-3. Online ahead of print. PMID: 39633050
Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration. Tregnago C, Benetton M, Ries RE, Peplinski JH, Alonzo TA, Stirewalt D, Othus M, Duployez N, Sonneveld E, Abrahamsson J, Fogelstrand L, von Neuhoff N, Hasle H, Reinhardt D, Meshinchi S, Locatelli F, Pigazzi M. J Clin Oncol. 2024 Dec 2:JCO2401715. doi: 10.1200/JCO-24-01715. Online ahead of print. PMID: 39621969
Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Othus M, Baccon D, Ali N, Rodríguez-Arbolí E, Orvain C, Milano F, Sandmaier BM, Davis C, Basom RS, Walter RB. Bone Marrow Transplant. 2024 Dec;59(12):1667-1675. doi: 10.1038/s41409-024-02407-y. Epub 2024 Aug 29. PMID: 39210036
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience. Huang IJ, Baek GT, Cohen J, Khajaviyan S, Louie S, Samples L, Smith SD, Till BG, Warren EH, Gopal AK, Poh C, Lynch RC, Ujjani CS, Shadman M. JCO Oncol Pract. 2024 Nov 18:OP2400416. doi: 10.1200/OP.24.00416. Online ahead of print .PMID: 39556786
Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. Pan C, Ng K, Voutsinas J, Barber B, Rizvi ZH, Marchiano E, Ferrandino RM, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Panjwani N, Martins RG, Rodriguez CP, Wu QV. BMC Cancer. 2024 Nov 15;24(1):1406. doi: 10.1186/s12885-024-13051-6. PMID: 39543541
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response. Liao JB, Dai JY, Reichow JL, Lim JB, Hitchcock-Bernhardt KM, Stanton SE, Salazar LG, Gooley TA, Disis ML.J Immunother Cancer. 2024 Nov 9;12(11):e010251. doi: 10.1136/jitc-2024-010251. PMID: 39521614
Phase 1 Study of ROR1 Specific CAR T Cells in Advanced Hematopoietic and Epithelial Malignancies. Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, MacMillan HR, Wu QV, Muhunthan V, Berger C, Pullarkat S, Wright JH, Yeung CCS, Hyun TS, Seaton B, Aicher LD, Song X, Pierce RH, Lo Y, Cole GO, Lee SM, Newell EW, Maloney DG, Riddell SR. Clin Cancer Res. 2024 Oct 28. doi: 10.1158/1078-0432.CCR-24-2172. Online ahead of print. PMID: 39466024
A phase 2 study of frontline pembrolizumab in follicular lymphoma. Ho C, Zhu S, Gooley T, Gujral TS, Lynch RC, Poh C, Shadman M, Smith SD, Tseng Y, Gopal AK. EJHaem. 2024 Oct 10;5(6):1173-1181. doi: 10.1002/jha2.1029. eCollection 2024 Dec. PMID: 39691260
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer. Liao JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, Reichow JL, Dang Y, Childs JS, Coveler AL, Swensen RE, Goff BA, Disis ML, Salazar LG. Gynecol Oncol. 2024 Oct 2;191:74-79. doi: 10.1016/j.ygyno.2024.09.019. Online ahead of print. PMID: 39362046